$NGNE
Neurogene Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · New York, NY
NGNE chart
What traders are saying about $NGNE
Latest postsNeurogene Inc. news
- Neurogene presents preclinical data on Rett syndrome therapy
Investing.com ·
- Neurogene presents NGN-401 gene therapy data at ESGCT congress
StreetInsider ·
- NGN-401 gene therapy data presented by Neurogene at European Congress
Traders Union ·
- Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
Yahoo Finance ·
- Rett trial participants showed improvement at a median of two months. It continued through 30 months.
Stock Titan ·
- Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy
BioSpace ·
- Neurogene Inc. Estimates – LSX:A3EX79
TradingView ·
- Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Yahoo Finance ·
- Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
Yahoo Finance ·
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Yahoo Finance ·
Neurogene Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $925,000 | $0 | – |
| Net income | -$90.4M | -$75.1M | -$36.3M | -$55.2M |
| Diluted EPS | $-4.24 | $-4.28 | – | $-1.04 |
| Total assets (year end) | $288.6M | $335.7M | $222.6M | $109.3M |
| Cash and equivalents (year end) | $103.8M | $136.6M | $148.2M | $82.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Neurogene Inc.
- Ticker
- NGNE (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- SEC CIK
- 1404644
- Former names
- Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, AQUINOX PHARMACEUTICALS (USA) INC
Frequently asked questions
What exchange is Neurogene Inc. listed on?
Neurogene Inc. trades on the Nasdaq under the ticker symbol NGNE.
What industry is Neurogene Inc. in?
Neurogene Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Neurogene Inc. headquartered?
Neurogene Inc.'s business address on file with the SEC is in New York, NY.
When does Neurogene Inc.'s fiscal year end?
Neurogene Inc.'s fiscal year ends on December 31.
How much revenue did Neurogene Inc. report?
Neurogene Inc. reported $0 in revenue for calendar year 2025, according to its SEC filings.